Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by enGene Holdings Inc.
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 31, 2025
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
January 30, 2025
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 30, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
December 19, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene to Participate in Upcoming Investor Conferences
November 25, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Announces $60 Million Private Placement Financing
October 25, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 22, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
October 21, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
September 26, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
September 10, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene to Participate in Upcoming Investor Conferences
August 28, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 24, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
July 24, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
June 14, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
May 15, 2024
From
enGene Holdings Inc.
Via
Business Wire
Tickers
ENGN
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.